Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Frequently asked questions
What sector does Walvax BioTech (300142) operate in?
Walvax BioTech belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Walvax BioTech (300142) current stock price?
As of the latest data, Walvax BioTech stock price is CN¥13.32, with a previous close of CN¥13.16. Walvax BioTech gained CN¥0.16 in the last trading session, representing a 1.22% increase.
What is Walvax BioTech (300142) current market capitalization?
Walvax BioTech market cap is approximately 21.30 billion.
What is Walvax BioTech (300142) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.18, and the forward EPS is CN¥0.21.
What is Walvax BioTech (300142) Price-to-Earnings (P/E) ratio?
Walvax BioTech current P/E ratio is 74, with a forward P/E of 63.43.
Does Walvax BioTech (300142) pay dividends?
Yes. Walvax BioTech pays semiannual dividends with an annualized yield of 1.88% and an estimated annual payout of CN¥0.25 per share.
When is the next ex-dividend date for Walvax BioTech (300142)?
The next ex-dividend date is scheduled for December 24, 2026.
How did Walvax BioTech (300142) perform in its most recent earnings report?
In the last report (March 31, 2026), Walvax BioTech posted an EPS surprise of 250% and a revenue surprise of -9.09%.
What is Walvax BioTech (300142) beta (volatility) score?
Walvax BioTech has a beta of 0.384, indicating lower volatility than the overall market.
